Rani Therapeutics Holdings, Inc.
Rani Therapeutics Holdings, Inc. (RANI) Revenue
Annual & quarterly revenue history · segment & region breakdown
RANI · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsRani Therapeutics Holdings, Inc. trailing twelve-month (TTM) revenue is $0.00B, an increase of 58.85% year-over-year from $0.00B in FY2025.
Revenue trend
2025 – 2019 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.00B | +$0.00B | +58.85% |
| 2024-12-31 | $0.00B | +$0.00B | — |
| 2023-12-31 | $0.00B | +$0.00B | — |
| 2022-12-31 | $0.00B | -$0.00B | -100.00% |
| 2021-12-31 | $0.00B | +$0.00B | +488.10% |
| 2020-12-31 | $0.00B | -$0.00B | -52.81% |
| 2019-12-31 | $0.00B | — | — |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Rani Therapeutics Holdings, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Rani Therapeutics Holdings, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Rani Therapeutics Holdings, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
RANI revenue · 4 questionsRANI's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 58.85% year-over-year from $0.00B in FY2025.
▸ Source: FMP · Rani Therapeutics Holdings, Inc. SEC filings · GAAP · Rani Therapeutics Holdings, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026